Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults

被引:35
|
作者
Talbot, TR
Crocker, DD
Peters, J
Doersam, JK
Ikizler, MR
Sannella, E
Wright, PF
Edwards, KM
机构
[1] Vanderbilt Univ, Ctr Med, Pediat Clin Res Off, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Ctr Med, Div Infect Dis, Dept Med, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Ctr Med, Div Infect Dis, Dept Prevent Med, Nashville, TN 37232 USA
[4] Vanderbilt Univ, Ctr Med, Div Infect Dis, Dept Pediat, Nashville, TN 37232 USA
来源
关键词
D O I
10.1086/502574
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE: To characterize the probability and duration of viral shedding among adults given trivalent live attenuated influenza vaccine (LAIV). DESIGN: Prospective surveillance study. METHODS: Nasal wash samples were collected from adult volunteers at baseline and on days 3, 7, and 10 and between days 17 and 21 following intranasal LAIV vaccination. The presence, titer, and identification of each specific strain of influenza virus shed were determined by standard methodology. RESULTS: Twenty subjects received LAIV. No samples were positive for influenza virus at baseline. After LAIV vaccination, influenza virus was recovered from 10 of 20 vaccinees on day 3, from 1 of 18 vaccinees on day 7, and from none of the samples on days 10 or 17 through 21. Vaccinees who shed vaccine virus were significantly younger than those who did not (mean age, 26.4 vs 38.6 years; P <.01). Although the presence of specific mucosal immunoglobulin A to influenza B was associated with significantly less shedding of influenza B after vaccination (P =.02), associations of shedding with other measures of immunity were not detected. CONCLUSION: The duration of shedding of vaccine virus after LAIV in adults is limited and may be associated with an individual's prior influenza vaccination history.
引用
收藏
页码:494 / 500
页数:7
相关论文
共 50 条
  • [41] Evaluation of the safety, immunogenicity and virus shedding of an intranasal live attenuated bovine parainfluenza virus type 3 vaccine in infants
    Greenberg, DP
    Yeh, S
    Yogev, R
    Reisinger, KS
    Ward, JI
    Blatter, MM
    Holmes, S
    Mendelman, PM
    Coelingh, KL
    Cho, I
    PEDIATRIC RESEARCH, 1999, 45 (04) : 161A - 161A
  • [42] Duration of Immunity Induced after Vaccination of Cattle with a Live Attenuated or Inactivated Lumpy Skin Disease Virus Vaccine
    Haegeman, Andy
    De Leeuw, Ilse
    Mostin, Laurent
    Van Campe, Willem
    Philips, Wannes
    Elharrak, Mehdi
    De Regge, Nick
    De Clercq, Kris
    MICROORGANISMS, 2023, 11 (01)
  • [43] Intranasal, cold-adapted, live, attenuated influenza vaccine
    Abramson, JS
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (12) : 1103 - 1104
  • [44] ENHANCED LYMPHOPROLIFERATION TO INFLUENZA-A VIRUS FOLLOWING VACCINATION OF OLDER, CHRONICALLY III ADULTS WITH LIVE-ATTENUATED VIRUSES
    GORSE, GJ
    BELSHE, RB
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1991, 23 (01) : 7 - 17
  • [45] Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children
    King, JC
    Fast, PE
    Zangwill, KM
    Weinberg, GA
    Wolff, M
    Yan, LH
    Newman, F
    Belshe, RB
    Kovacs, A
    Deville, JG
    Jelonek, M
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (12) : 1124 - 1131
  • [46] Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children
    Bernstein, DI
    Yan, LH
    Treanor, J
    Mendelman, PM
    Belshe, R
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (01) : 28 - 34
  • [48] TRIVALENT ATTENUATED COLD-ADAPTED INFLUENZA-VIRUS VACCINE - REDUCED VIRAL SHEDDING AND SERUM ANTIBODY-RESPONSES IN SUSCEPTIBLE ADULTS
    KEITEL, WA
    COUCH, RB
    QUARLES, JM
    CATE, TR
    BAXTER, B
    MAASSAB, HF
    JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (02): : 305 - 311
  • [49] Adverse events following live-attenuated intranasal influenza vaccination of children with cystic fibrosis: Results from two influenza
    Boikos, Constantina
    Joseph, Lawrence
    Scheifele, David
    Lands, Larry C.
    De Serres, Gaston
    Papenburg, Jesse
    Winters, Nicholas
    Chilvers, Mark
    Quach, Caroline
    VACCINE, 2017, 35 (37) : 5019 - 5026
  • [50] 538 Severity of Breakthrough Influenza Illness Among Children and Adults Receiving Live Attenuated Influenza Vaccine and Trivalent Inactivated Influenza Vaccine
    R B Belshe
    C S Ambrose
    R Pilsudski
    Pediatric Research, 2010, 68 : 275 - 275